⌘K
Loading ticker…
As of 2026-08-24, Lineage Cell Therapeutics, Inc. (LCTX) has a 3-month relative strength percentile of 23 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 41. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 4.9%, relative volume 0.64×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
LCTX is in a stage 4 downtrend, week 7. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -7.0% / -27.2%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
LCTX is held by 3 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $9M notional. Top 3 carry $15M.
Held by 3 ETFs · $15M across latest filings · largest weight 0.03% (IBB).
Top 3 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $9M | — |
| VXFVanguard Extended Market ETF | 0.01% | $4M | — |
| IBB | 0.03% | $3M | new |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | LCTX Jan avg: 4.57% median: 4.08% win: 50% σ: 20.47% n: 4 2022-04-12 → 2026-07-31 | LCTX Feb avg: 6.87% median: 2.65% win: 50% σ: 17.64% n: 4 2022-04-12 → 2026-07-31 | LCTX Mar avg: 4.03% median: -3.30% win: 50% σ: 29.13% n: 4 2022-04-12 → 2026-07-31 | LCTX Apr avg: -7.30% median: -6.87% win: 20% σ: 13.15% n: 5 2022-04-12 → 2026-07-31 | LCTX May avg: 1.63% median: -7.35% win: 40% σ: 18.44% n: 5 2022-04-12 → 2026-07-31 | LCTX Jun avg: 14.61% median: 11.91% win: 60% σ: 16.64% n: 5 2022-04-12 → 2026-07-31 | LCTX Jul avg: 2.09% median: 3.80% win: 80% σ: 11.60% n: 5 2022-04-12 → 2026-07-31 | LCTX Aug avg: -6.81% median: -13.88% win: 25% σ: 14.34% n: 4 2022-04-12 → 2026-07-31 (current) | LCTX Sep avg: 4.10% median: -4.09% win: 50% σ: 28.41% n: 4 2022-04-12 → 2026-07-31 | LCTX Oct avg: 6.04% median: 5.11% win: 50% σ: 14.22% n: 4 2022-04-12 → 2026-07-31 | LCTX Nov avg: -12.08% median: -11.10% win: 25% σ: 15.02% n: 4 2022-04-12 → 2026-07-31 | LCTX Dec avg: -6.39% median: -8.62% win: 25% σ: 12.96% n: 4 2022-04-12 → 2026-07-31 |